In the studies being conducted at Dartmouth, researchers will employ a multi-modality approach that may impact diagnosis and treatment of cardiovascular disease and various cancers in the breast and brain. For example, an enhanced ability to assess tissue viability in a reliable manner would be an important clinical tool in cardiovascular disease. The combination of imaging plaque in new vessels with PET imaging would increase the reliability of non-invasive detection of fatty substances along the artery wall.

"Philips Medical Systems is deeply committed to advancing the diagnosis and treatment of diseases to enhance patient care through innovative research," said Diego Olego, senior vice president and chief technology officer, for Philips Medical Systems. "Working side-by-side with a prestigious medical school like Dartmouth, we will establish ways to improve and develop imaging solutions that address some of the world's more prevalent diseases."


Alternative Breast Cancer Imaging Center

The Alternative Breast Cancer Imaging Center (ABCIC) at Dartmouth develops and evaluates alternatives to current imaging methods to increase the accuracy of breast cancer detection and diagnosis, and monitoring of breast cancer progression and regression. A superb cadre of researchers from the Thayer School and the Norris Cotton Cancer Center combine technological developments with clinical studies to explore emerging technologies that can contribute to breast imaging, including Magnetic Resonance Elastography (MRE); and Near Infrared Spectral Imaging (NIR).

Advanced Cardio-Vascular Imaging

Through this collaboration with Philips, Dartmouth will have the ability to perform research with micro positron emission tomography (microPET), as well as other imaging technologies over the course of the relationship. These new imaging technologies will enable scientists to test and define new molecular imaging technologies, which may allow the identification of changes in the structures and functions of myocardial tissue, as well as tumor cells for brain, breast and prostate cancer. Understanding cell function at the molecular level can lead to more accurate treatment delivery and outcomes while minimizing side effects.

Norris Cotton Cancer Center's Imaging Program

The Norris Cotton Cancer Center (NCCC), a National Cancer Institute-designated Comprehensive Cancer Center, is developing an imaging program to enhance early tumor detection, facilitate the development and evaluation of new drugs, and accelerate the development of new therapies to improve the quality of life for cancer patients. Researchers are working to elucidate molecular events underlying malignant tumors to help prevent cancer before it starts.

More Industry Headlines